NCT03258879

Brief Summary

Epidural, Combined Spinal-Epidural, and more recently dural puncture epidural are forms of neuraxial anesthesia used to provide pain relief in laboring women . The investigators want to assess the onset of pain relief with 2 different neuraxial techniques performed at our center, but which have not yet been compared in the literature: (1) Modified CSE, with only local anesthetic injected into the spinal fluid to reduce side effects of opioids that are seen with the traditional CSE and (2) Dural Puncture Epidural (DPE), involving puncture of the spinal membrane, but without injection of medication into the spinal space. The investigators hypothesize that the onset of labor analgesia will be faster with modified CSE compared to DPE.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2018

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 12, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 23, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

January 1, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2018

Completed
Last Updated

November 14, 2017

Status Verified

November 1, 2017

Enrollment Period

7 months

First QC Date

July 12, 2017

Last Update Submit

November 9, 2017

Conditions

Keywords

Combined spinal epidural analgesia, dural puncture epidural

Outcome Measures

Primary Outcomes (1)

  • Comparison of the onset of effective analgesia between the study techniques

    Numerical Rating Scale (NRS) for pain \</= 1/10 in minutes

    1 year

Secondary Outcomes (3)

  • Comparison of block quality between the study techniques

    1 year

  • Comparison of the incidence of pruritus between the study techniques

    1 year

  • Comparison of the incidence of fetal bradycardia between the study techniques

    1 year

Study Arms (2)

Modified CSE

EXPERIMENTAL

MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally

Procedure: Modified CSE

Dural puncture epidural

ACTIVE COMPARATOR

Dural puncture performed with a spinal needle, but no medication will be injected intrathecally.

Procedure: Dural puncture epidural

Interventions

Modified CSEPROCEDURE

MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally

Modified CSE

DPE group: Dural puncture performed, but no medication will be injected intrathecally.

Dural puncture epidural

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant patients
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • ASA II healthy adult parturients, at 37-40 weeks gestation with singleton pregnancy and vertex presentation.
  • Parturients in early labor with cervical dilatation less than 6 cm requesting epidural analgesia
  • Parturients able to provide written informed consent.

You may not qualify if:

  • Patient refusal to participate in the study.
  • Presence of clinically significant disease
  • Contraindications to neuraxial analgesia.
  • Presence of conditions associated with an increased risk of a cesarean delivery like history of uterine anomaly or surgery, morbid obesity and known fetal anomalies or non-reassuring fetal heart rate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Indu Singh, MD, FRCPC

    Western University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yamini Subramani, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 12, 2017

First Posted

August 23, 2017

Study Start

January 1, 2018

Primary Completion

August 1, 2018

Study Completion

August 1, 2018

Last Updated

November 14, 2017

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will not share